key: cord-0753144-ptiqzhbd
authors: Wang, Ying-Ting; Allen, Robert D.; Kim, Kenneth; Shafee, Norazizah; Gonzalez, Andrew J.; Nguyen, Michael N.; Valentine, Kristen M.; Cao, Xia; Lu, Lucy; Pai, Chin-I; Johnson, Sachi; Kerwin, Lisa; Zhou, Heyue; Zhang, Yanliang; Shresta, Sujan
title: SARS-CoV-2 monoclonal antibodies with therapeutic potential: Broad neutralizing activity and No evidence of antibody-dependent enhancement
date: 2021-10-08
journal: Antiviral Res
DOI: 10.1016/j.antiviral.2021.105185
sha: 6447e3d7da1040aea49c7b8f1f5e6e0c8b18b905
doc_id: 753144
cord_uid: ptiqzhbd

Monoclonal antibodies (mAbs) are emerging as safe and effective therapeutics against SARS-CoV-2. However, variant strains of SARS-CoV-2 have evolved, with early studies showing that some mAbs may not sustain their efficacy in the face of escape mutants. Also, from the onset of the COVID-19 pandemic, concern has been raised about the potential for Fcγ receptor-mediated antibody-dependent enhancement (ADE) of infection. In this study, plaque reduction neutralization assays demonstrated that mAb 1741-LALA neutralizes SARS-CoV-2 strains B.1.351, D614 and D614G. MAbs S1D2-hIgG1 and S1D2-LALA mutant (STI-1499-LALA) did not neutralize B.1.351, but did neutralize SARS-CoV-2 strains D614 and D614G. LALA mutations did not result in substantial differences in neutralizing abilities between clones S1D2-hIgG1 vs STI-1499-LALA. S1D2-hIgG1, STI-1499-LALA, and convalescent plasma showed minimal ability to induce ADE in human blood monocyte-derived macrophages. Further, no differences in pharmacokinetic clearance of S1D2-hIgG1 vs STI-1499-LALA were observed in mice expressing human FcRn. These findings confirm that SARS-CoV-2 has already escaped some mAbs, and identify a mAb candidate that may neutralize multiple SARS-CoV-2 variants. They also suggest that risk of ADE in macrophages may be low with SARS-CoV-2 D614, and LALA Fc change impacts neither viral neutralization nor Ab clearance.

(2019-nCoV) Spike S1-B.1.1.7 lineage mut (HV69-70 deletion, Y144 deletion, N501Y, 158 A570D, D614G, P681H)-His, SARS-CoV-2 (2019-nCoV) Spike S1-B.1.351 lineage mut 159 (K417N, E484K, N501Y, D614G)-His and Spike S1-B.1.617.2 lineage mut (T19R, G142D, 

Anti-SARS-CoV-2 mAbs S1D2-hIgG1, S1D2-LALA mutant (STI-1499-LALA) and LALA were generated at Sorrento Therapeutics, Inc. These three mAbs were each 171 expressed in Chinese hamster ovary (CHO) cells and purified by Protein A affinity 172 chromatography. Plasma samples from convalescent COVID-19 patients were tested in 173 this study. Two males and one female (aged 23 to 65-year-old), six to eight weeks from 174 being tested positive for SARS-CoV-2 were enrolled from Scripps Clinic Bio-Repository 175 & Bio-Informatics Core under La Jolla Institute for Immunology protocol IB-233-0820. 176 177

Vero E6 cells were plated at 8 x 10 4 cells/well in a 24-well plate one day prior to infection. 179 COVID-19 patient serum or anti SARS-CoV-2 mAbs were serially diluted and then 180 incubated with 30-40 plaque forming units (PFU) of virus for 1 h at 37°C. The 181 antibody/virus mixture was further transferred onto Vero E6 cells for 1 h at 37°C. The 182

infectious media was removed afterward and 1% carboxymethylcellulose medium was 183 overlaid onto each well. After 3 days incubation, the cells were fixed with 10 % 184 formaldehyde for 1h at RT and then stained with 0.1% crystal violet solution. All the conditions were performed in duplication. Antibody titers (PRNT50) were defined as the 186 highest serum dilution that reduce 50% of virus plaques. 187 188 2.8. Antibody dependent enhancement (ADE) assay 189

Serial diluted COVID-19 patient serum or anti SARS-CoV-2 mAb was incubated with 190 SARS-CoV-2 D614 at multiplicities of infection (MOI) of 0.25 and 1 for 1 h at 37°C. The 191 antibody/virus mixture was further transferred onto 7 day-differentiated human monocyte-192 derived macrophages for 1 h at 37° C. The infectious media was removed, and the cells 193

were washed once with PBS before adding fresh pre-warmed complete macrophage 194 medium. After 2 dpi, culture supernatant was collected for plaque assays to determine 195 the level of infectious viral particles as described previously, and infected cells were lysed 196 with RLT lysis buffer (Qiagen) supplemented freshly with 1% of 2-Mercaptoethanol (Gibco) 197 for 1h at RT. RNA from lysed cells was isolated (Qiagen) and SARS-CoV-2 genomic RNA 198 for E gene was detected by qRT-PCR. 199 200

Statistics and graphs were prepared using Prism software version 9.1.0 (GraphPad 202 Software) and are expressed as the mean ± standard deviation (SD). Statistically 203 differences between ADE groups were determined using one-way ANOVA. The 204 pharmacokinetic difference of serum human IgG between S1D2-hIgG1 and LALA mutant 205 was evaluated with non-parametric Mann-Whitney test. p < 0.05 was considered 206 significant. Further details on statistical analysis are listed in the figure legends. 

MAb clones S1D2-hIgG1, S1D2-LALA Fc (STI-1499-LALA) and 1741-LALA originated as 212 a single chain variable fragment (scFv) isolated from the Sorrento G-MAB library, a 213 phage-display library with an estimated coding complexity of approximately 10 10 unique antibody sequences derived from over 600 healthy individuals, as screened (Cao et al., 215 2020) . The library was panned using the Spike protein S1 fragment derived from the 216 SARS-CoV-2/human/USA/WA-CDC-WA1/2020 (USA-WA1/2020, GenBank: 217 MN985325.1). ScFv fragments with potent Spike S1 binding properties were further 218 confirmed with the capacity to block interactions between Spike S1 and a recombinant 219 ACE2 ectodomain by competition ELISA. Candidates are sequenced, reformatted with 220 CHO-S cells to a full-length human IgG1 or a human IgG1 with LALA mutations in the 221 hinge region and purified by affinity chromatography. Candidates were further evaluated 222 in a USA-WA1/2020 virus neutralization assay and mAb clones S1D2-hIgG1, STI-1499-223 LALA, and 1741-LALA were selected as among the most potent neutralizing antibodies 224 of the candidates isolated from the original library screen. Binding affinity of clones S1D2-225 hIgG1, STI-1499-LALA, and 1741-LALA to Spike S1 derived from 2019-nCoV was further 226 confirmed by ELISA (Figure 1a) . Clone S1D2-hIgG1, STI-1499-LALA also showed 227 binding affinity to Spike S1 derived from B.1.617.2 lineage with 50% binding inhibition 228 (IC50) at 411.2 and 561.1 ng/mL. Additionally, clone 1741-LALA revealed strong binding 229 affinity to Spike S1 harboring SARS-CoV-2 B. Emerging evidence shows SARS-CoV-2 variant resistance to convalescent plasma 239 (Hoffmann et al., 2021; Planas et al., 2021) and mAbs targeting the original pandemic 240 SARS-CoV-2 strain D614 (Tada et al., 2021; Wang et al., 2021) . To determine the 241 neutralizing abilities of mAbs 1741-LALA, S1D2-hIgG1, and STI-1499-LALA, we used the 242 50% plaque reduction neutralization test (PRNT50) to assess the capacities of these mAbs 243 to neutralize SARS-CoV-2 strains B.1.351, D614, and D614G. We compared the mAb 244 neutralizing abilities to convalescent plasma samples from three COVID-19 patients who 245 J o u r n a l P r e -p r o o f had previously tested positive for SARS-CoV-2. Plasma samples neutralized SARS-CoV-246 2 D614 as expected at dilutions ranging from 1:101 -1:38 (Fig 1c) . MAbs S1D2-hIgG1 247 and STI-1499-LALA neutralized SARS-CoV-2 strains D614 and D614G but not B.1.351 248 (Figs 1d-e) . In contrast, 1741-LALA neutralized B.1.351 at a PRNT50 concentration of 249 272.7 ng/mL (Fig 1f) . MAb 11741-LALA also neutralized SARS-CoV-2 D614 and D614G 250 at 1434.7 and 111.4 ng/mL, respectively (Figs 1d-e) . Thus among the three mAbs tested, 251 mAb 1741-LALA demonstrated the broadest spectrum of neutralization at the lowest 252 concentration. 253 254 LALA mutated antibodies are designed to prevent mAbs from binding FcγR and prevent 255 adverse consequences such as ADE, while not impacting neutralizing ability (Magnani et 256 al., 2017) . For SARS-CoV-2 strain D614, the PRNT50 concentrations of S1D2-hIgG1 and 257 STI-1499-LALA were comparable at 1685 ng/mL and 2312.7 ng/mL, respectively (Fig 1d) . 258

For strain D614G the PRNT50 concentrations of S1D2-hIgG1 and STI-1499-LALA were 259 also comparable at 694.3 ng/mL and 733.2 ng/mL, respectively (Fig 1e) . Thus no 260 substantial difference in neutralizing ability was seen between the WT Ab and the LALA 261 replication ensues (Ngono and Shresta, 2018) . Because macrophages are recognized as 273 being susceptible to ADE and have also been implicated in cytokine storm, we tested the 274 mAbs in this study for SARS-CoV-2 D614 ADE in human blood monocyte-derived 275 macrophages as previously described for Zika virus (Carlin et al., 2018) . 276

To assess the risk of ADE mediated by a diverse/polyclonal pool of Abs, we serially diluted 277 convalescent plasma samples from 3 donors who had recovered from SARS-CoV-2 278 between March to May in 2020 and incubated these dilutions with SARS-CoV-2 D614 at 279 multiplicities of infection (MOIs) of 0.25 and 1. These immune-complex solutions were 280 then inoculated onto monocyte-derived macrophages from 3-4 donors. At 2 days post-281 infection, supernatants were evaluated by plaque forming assay on Vero E6 cells and 282

infected cells were lysed and tested for viral genomic RNA for E gene by RT-283 qPCR (Corman et al., 2020) . At all four plasma dilutions ranging from 0.004% to 4%, 284 minimal increase in viral RNA (Figs 2b-c) and supernatant virus (Figs 2d-e) was seen 285 for any of the plasma-macrophage donor pairs. This contrasted with our control 286 experiment in which a higher percentage of Zika virus E protein-expressing cells were 287 detected in macrophage cultures incubated with pan-flavivirus humanized mAb 4G2 at 288 concentrations of 0.000032 mg/mL and higher (Fig 2a) . 289 290 Next, to assess the risk of ADE mediated by the mAbs in this study, clones S1D2-hIgG1, macrophage donor pairs. Thus no evidence of SARS-CoV-2 D614 ADE was seen with 296 WT Fc mAbs, LALA Fc mAbs, or convalescent plasma, and together these data suggest 297 the risk of ADE in macrophages may be low with D614. 298 299

IgG plasma half-life is largely determined by binding affinity of the neonatal Fc receptor 301 at acidic pH (FcRn; encoded by the FCGRT gene) to its binding site at an Ab's Fc region, 302 and binding is then further modulated by pH (Roopenian and Akilesh, 2007 mouse is also knocked out for the interferon-α/β receptor (Ifnar1). Mice were injected 311 with a single 5 mg/kg dose of S1D2-hIgG1 or STI-1499-LALA. Sera were then harvested 312 after 30 min, 1h, 8h, 1d, 7d, 14d, 21d and 28d to measure human IgG by ELISA. No 313 significant difference was seen between the clearance curves of S1D2-hIgG1 vs STI-314 1499-LALA (Fig 3e) , indicating that the pharmacokinetics of anti-SARS-CoV-2 mAb S1D2 Zika virus infection while retaining the same neutralizing abilities as unmodified parental 364 mAbs (Beltramello et al., 2010; Khandia et al., 2018; Xu et al., 2017) . However, Fc-365 effector function has been shown to decrease viral load by 6-14-fold in SARS-CoV-2 366 infected mouse lungs (Winkler et al., 2021) . Finally, no differences in pharmacokinetic 367 clearance of S1D2-hIgG1 vs STI-1499-LALA were observed in mice expressing human 368 J o u r n a l P r e -p r o o f FcRn. These findings indicate that either WT Fc or LALA mutant Abs may be deployed 369 as SARS-CoV-2 therapeutics without concern for altering clearance or resulting efficacy. Dejnirattisai, W., Supasa, P., Liu, C., Mentzer, A.J., Ginn, H.M., Zhao, Y., 578 Duyvesteyn, H.M.E., Tuekprakhon, A., Nutalai, R., Wang, B., Paesen, G.C., Lopez-579

Camacho, C., J., Hallis, B., Coombes, N., Bewley, K., Charlton, S., Walter, 580 T.S., Skelly, D., Lumley, S.F., Dold, C., Levin, R., Dong, T., Pollard, A.J., Knight, J.C., 581

Crook, D., Lambe, T., Clutterbuck, E., Bibi, S., Flaxman, A., Bittaye, M., Belij-582

Rammerstorfer, S., Gilbert, S., James, W., Carroll, M.W., Klenerman, P., Barnes, E., 583

Dunachie, S.J., Fry, E.E., Mongkolsapaya, J., Ren, J., Stuart, D.I., Screaton, G.R., 2021. 584 Evidence of escape of SARS-CoV-2 variant B. 

A perspective on potential antibody-446 dependent enhancement of SARS-CoV-2

The 450 human immune response to Dengue virus is dominated by highly cross-reactive 451 antibodies endowed with neutralizing and enhancing activity

Dengue Virus Immunity Increases Zika 456 Virus-Induced Damage during Pregnancy

Discovery and 460 Development of Human SARS-CoV-2 Neutralizing Antibodies using an Unbiased Phage 461 Display Library Approach

Deconvolution of pro-and antiviral 464 genomic responses in Zika virus-infected and bystander macrophages

Growth, detection, 467 quantification, and inactivation of SARS-CoV-2

Resistance of SARS-CoV-2 variants to 473 neutralization by monoclonal and serum-derived polyclonal antibodies

Cytokine responses in severe acute respiratory 477 syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis

Detection of 483 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Dengue virus sero-cross-reactivity drives immunology 17

Maternally Acquired Zika Antibodies Enhance Dengue Disease 492 Severity in Mice

Circuits between infected macrophages and T cells in SARS-500

CoV-2 pneumonia

Intrinsic 502 antibody-dependent enhancement of microbial infection in macrophages: disease 503 regulation by immune complexes

507 SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies

The neutralizing antibody, LY-CoV555, protects against SARS-518

CoV-2 infection in nonhuman primates

Modulation of Dengue/Zika Virus Pathogenicity by Antibody-521

Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus 522 Infection

Molecular therapy : the journal of the American Society of Gene Therapy 25

Efficacy of Remdesivir in COVID-19

J o u r n a l P r e -p r o o f Declaration of interests ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: